Survivorship Issues in Adult Patients With Histiocytic Neoplasms

Author:

O’Brien Kevin1,Dave Rahul2,Shekhar Skand34,Hannah-Shmouni Fady4,Comis Leora E.5,Solomon Beth I.6,Chen Marcus7,Gahl William A.1,FitzGibbon Edmond8,Gochuico Bernadette R.1,Estrada-Veras Juvianee I.1

Affiliation:

1. 1Office of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland;

2. 2Inova Fairfax-Virginia Commonwealth University College of Medicine, Falls Church, Virginia;

3. 3Clinical Research Branch, National Institute of Environmental Health Sciences, NIH, Bethesda, Maryland;

4. 4Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland;

5. 5Rehabilitation Medicine Department, Clinical Center, NIH, Bethesda, Maryland;

6. 6Speech Language Pathology Section, Rehabilitation Medicine Department, Mark O. Hatfield Clinical Research Center, NIH, Bethesda, Maryland;

7. 7National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; and

8. 8National Eye Institute, NIH, Bethesda, Maryland.

Abstract

Adult-onset histiocytoses (AOH), primarily Rosai-Dorfman disease (RDD), Erdheim-Chester Disease (ECD), and adult Langerhans cell histiocytosis (ALCH), are a group of related histiocytic neoplastic disorders featuring multisystemic manifestations. The disorders are largely incurable, and are essentially chronic neoplastic diseases with a variable prognosis. Prompt diagnosis and treatment is important to prevent debilitating and even life-threatening complications. Survivorship issues abound in AOH, due to their multisystemic manifestations and the sometimes recalcitrant chronic inflammation, which can lead to other debilitating complications such as fatigue, weakness, and pain. Because these disorders are rare, few healthcare professionals are proficient in their management; therefore the aim of these guidelines is to offer guidance on how to manage patients, and how to create survivorship care plans through the efforts of an interdisciplinary team.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3